SERO Serologicals (MM)

Serologicals Corporation (NASDAQ:SERO) announced today that its stockholders overwhelmingly approved the proposed acquisition of Serologicals by Millipore Corporation at a special stockholders' meeting held today in New York City. Harold W. Ingalls, the Vice President, Finance and Chief Financial Officer of Serologicals, stated that 28,172,696 shares of Serologicals Common Stock were present in person or by proxy at the special meeting, representing approximately 82.4% of the shares outstanding on the record date for the special meeting. Holders of 28,143,760 shares, or approximately 82.3% of the shares outstanding on the record date, voted in favor of the adoption of the Agreement and Plan of Merger among Serologicals, Millipore and Millipore's acquisition subsidiary. David A. Dodd, the President and Chief Executive Officer of Serologicals, commented regarding the special meeting, stating "I am very pleased that our shareowners so resoundingly approved our transaction with Millipore. This combination of two outstanding companies will create a company with leading products in many important areas of the life sciences tools industry. The tremendous increase in value of Serologicals over the past several years is a tribute to the focus on value creation by our outstanding employees worldwide. It has been a great pleasure working with and representing this team. Millipore is an outstanding organization and we wish them the very best of continued success." Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. The Company's products and technologies are used in a wide variety of innovative applications within the areas of oncology, hematology, immunology, cardiology and infectious diseases, as well as in the study of molecular biology. Serologicals has approximately 1,000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. On April 25, 2006, Serologicals entered into an Agreement and Plan of Merger with Millipore Corporation and one of its wholly-owned subsidiaries, pursuant to which Millipore Corporation will acquire Serologicals. This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements, including general industry and market conditions. Additional information concerning these and other risks and uncertainties is outlined in Serologicals' filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006. This report is available online at http://www.sec.gov. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and Serologicals undertakes no obligation to update these statements based on events that may occur after the date of this press release. Serologicals is a registered trademark of Serologicals Royalty Company.